270 related articles for article (PubMed ID: 15735127)
1. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
Starczynski J; Pepper C; Pratt G; Hooper L; Thomas A; Milligan D; Bentley P; Fegan C
J Clin Oncol; 2005 Mar; 23(7):1514-21. PubMed ID: 15735127
[TBL] [Abstract][Full Text] [Related]
2. G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression.
Moshynska O; Moshynskyy I; Misra V; Saxena A
Oncogene; 2005 Mar; 24(12):2042-9. PubMed ID: 15688029
[TBL] [Abstract][Full Text] [Related]
3. The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia.
Skogsberg S; Tobin G; Kröber A; Kienle D; Thunberg U; Aleskog A; Karlsson K; Laurell A; Merup M; Vilpo J; Sundström C; Roos G; Jernberg-Wiklund H; Döhner H; Nilsson K; Stilgenbauer S; Rosenquist R
Leukemia; 2006 Jan; 20(1):77-81. PubMed ID: 16307023
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2002; 49(6):387-93. PubMed ID: 12584586
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.
Bannerji R; Kitada S; Flinn IW; Pearson M; Young D; Reed JC; Byrd JC
J Clin Oncol; 2003 Apr; 21(8):1466-71. PubMed ID: 12697868
[TBL] [Abstract][Full Text] [Related]
8. The relevance of sequence insertions in the Mcl-1 promoter in chronic lymphocytic leukemia and in normal cells.
Coenen S; Pickering B; Potter KN; Johnson PW; Stevenson FK; Packham G
Haematologica; 2005 Sep; 90(9):1285-6. PubMed ID: 16154859
[TBL] [Abstract][Full Text] [Related]
9. The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Norberg M; Murray F; Merup M; Sundström C; Roos G; Aleskog A; Karlsson K; Axelsson T; Tobin G; Rosenquist R
Leukemia; 2008 Feb; 22(2):339-43. PubMed ID: 18046447
[TBL] [Abstract][Full Text] [Related]
10. Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia.
Kochethu G; Delgado J; Pepper C; Starczynski J; Hooper L; Krishnan S; Fegan C; Pratt G
Leuk Res; 2006 Sep; 30(9):1113-8. PubMed ID: 16458962
[TBL] [Abstract][Full Text] [Related]
11. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia.
Saxena A; Viswanathan S; Moshynska O; Tandon P; Sankaran K; Sheridan DP
Am J Hematol; 2004 Jan; 75(1):22-33. PubMed ID: 14695629
[TBL] [Abstract][Full Text] [Related]
12. Abnormal intracellular level of Bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients.
Scamardella F; Maconi M; Albertazzi L; Gamberi B; Gugliotta L; Brini M
Lab Hematol; 2006; 12(4):187-92. PubMed ID: 17118768
[TBL] [Abstract][Full Text] [Related]
13. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
14. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck.
Chen K; Hu Z; Wang LE; Sturgis EM; El-Naggar AK; Zhang W; Wei Q
Carcinogenesis; 2007 Sep; 28(9):2008-12. PubMed ID: 17693666
[TBL] [Abstract][Full Text] [Related]
15. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
Iglesias-Serret D; Coll-Mulet L; Santidrián AF; Navarro-Sabaté A; Domingo A; Pons G; Gil J
J Natl Cancer Inst; 2005 Jul; 97(14):1090-1; author reply 1093-5. PubMed ID: 16030310
[No Abstract] [Full Text] [Related]
16. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
Nenning UC; Eckert C; Wellmann S; Barth A; Henze G; Seeger K
J Natl Cancer Inst; 2005 Jul; 97(14):1091-2; author reply 1093-5. PubMed ID: 16030311
[No Abstract] [Full Text] [Related]
17. Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.
Dicker F; Rauhut S; Kohlmann A; Kern W; Schoch C; Haferlach T; Schnittger S
J Natl Cancer Inst; 2005 Jul; 97(14):1092-3; author reply 1093-5. PubMed ID: 16030312
[No Abstract] [Full Text] [Related]
18. Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia.
Bogunia-Kubik K; Mazur G; Urbanowicz I; Wróbel T; Kuliczkowski K; Woźniak M; Lange A
Int J Immunogenet; 2006 Feb; 33(1):21-4. PubMed ID: 16426238
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells.
Bogner C; Sandherr M; Perker M; Weick K; Ringshausen I; Peschel C; Decker T
Ann Hematol; 2006 Jul; 85(7):458-62. PubMed ID: 16538501
[TBL] [Abstract][Full Text] [Related]
20. Sequence-based polymorphisms in members of the apoptosis Bcl-2 gene family and their association with hematocrit level.
Zeng SM; Yankowitz J; Widness JA; Strauss RG
J Gend Specif Med; 2003; 6(4):36-42. PubMed ID: 14714449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
